TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Takeda Pharmaceutical Company ( (TAK) ) has provided an announcement.
In November 2025, Takeda Pharmaceutical Company announced significant advancements in its late-stage pipeline, including positive Phase 3 data for rusfertide and oveporexton, targeting polycythemia vera and narcolepsy type 1, respectively. These developments, along with anticipated regulatory submissions and commercialization preparations, are expected to drive substantial growth, with potential peak revenue between USD 10 and 20 billion. The company also highlighted its strategic partnership with Innovent Biologics, reinforcing its commitment to expanding its R&D pipeline and delivering transformative treatments. Additionally, Takeda is undergoing a leadership transition with Julie Kim set to become CEO in June 2026, ensuring continuity and future acceleration.
The most recent analyst rating on (TAK) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Company stock, see the TAK Stock Forecast page.
Spark’s Take on TAK Stock
According to Spark, TipRanks’ AI Analyst, TAK is a Neutral.
Takeda Pharmaceutical’s overall stock score reflects a stable financial position with strong cash flow generation but faces challenges in revenue growth and profitability. The technical analysis indicates a bearish trend, and the high P/E ratio suggests potential overvaluation despite a strong dividend yield. The earnings call highlighted both opportunities in pipeline advancements and strategic partnerships, as well as risks from VYVANSE’s generic impact and currency headwinds.
To see Spark’s full report on TAK stock, click here.
More about Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Tokyo, Japan. It operates in the healthcare industry, focusing on developing and delivering innovative treatments across various therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases, plasma-derived therapies, and vaccines.
Average Trading Volume: 2,974,843
Technical Sentiment Signal: Buy
Current Market Cap: $45.97B
Find detailed analytics on TAK stock on TipRanks’ Stock Analysis page.